会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Aza-bicycles which modulate the inhibition of cell adhesion
    • 调节细胞粘附抑制的Aza-自行车
    • US06608084B1
    • 2003-08-19
    • US09856106
    • 2001-10-17
    • Jean-Dominique BourzatAlain CommerconBruno Jacques Christophe FilocheNeil Victor HarrisClive McCarthy
    • Jean-Dominique BourzatAlain CommerconBruno Jacques Christophe FilocheNeil Victor HarrisClive McCarthy
    • A61K3147
    • C07D401/12C07D209/12C07D215/08C07D215/14C07D405/04C07D413/06C07D413/12
    • The invention is directed to physiologically active compounds of formula (I) wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C1-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)R9, —N(R8)—SO2—R9, —NY4Y5 or —[C(═O)—N(R10)—C(R5)(R11)]p—C(═O)—NY4Y5, or by (b) alkyl substituted by an acidic functional group, or S(O)mR9, —C(═O)—NY4Y5 or —NY4Y5; a —[C(═O)—N(R10)—C(R5)(R11)]p— linkage; a —Z2—R12— linkage; a —C(═O)—CH2—C(═O)— linkage; a —R12—Z2—R12— linkage; a —C(R4)(R13)—[C(═O)—N(R10)—C(R5)(R11)]p— linkage; or a —L5—L6—L7— linkage; Z1 is C(R7)(R7a), C(═O) or CH(OH); Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
    • 本发明涉及式(I)的生理活性化合物,其中R1表示R3-Z3-,R3-L2-R4-Z3-,R3-L3-Ar1-L4-Z3-或R3-L3-Ar1-L2-R4 -Z3-; R2代表氢,卤素,低级烷基或低级烷氧基; A1表示任选被一个或多个选自烷基,芳基,芳基烷基,杂芳基,杂芳基烷基,亚氨基,氧代,硫代或被-ZR 6,-NY 1 Y 2,-CO 2 R 6或-C( = O)-NY1Y2; L1表示直接键; 各自任选被(a)酸性官能团氰基,氧代,-S(O)m R 9,R 3,-C(= O)-R 3中的一个取代的亚烯基,亚烷基,亚炔基,亚环烯基,亚环烷基,杂芳基二基,亚杂环基或亚芳基 ,-C(= O)-OR3,-N(R8)-C(= O)R9,-N(R8)-SO2-R9,-NY4Y5或 - [C(= O)-N(R10)-C (R 5)(R 11)] p C(= O)-NY 4 Y 5或(b)被酸性官能团取代的烷基或S(O)m R 9,-C(= O)-NY 4 Y 5或-NY 4 Y 5; a - [C(= O)-N(R 10)-C(R 5)(R 11)] p-键; a -Z2-R12-键; 一个-C(= O)-CH 2